The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landscape of genomic alterations of circulating tumor DNA in advanced genitourinary cancer patients: SCRUM-Japan MONSTAR SCREEN Project.
 
Nobuaki Matsubara
Honoraria - AstraZeneca; Bayer; Chugai Pharma (Inst); Janssen; MSD
Consulting or Advisory Role - AstraZeneca; Janssen; Lilly; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)
 
Taigo Kato
No Relationships to Disclose
 
Takao Fujisawa
No Relationships to Disclose
 
Masaki Shiota
Honoraria - Astellas Pharma; Bayer Yakuhin; Janssen; Sanofi; Takeda
 
Masatoshi Eto
Consulting or Advisory Role - Bristol-Myers Squibb; Chugai Pharma; Eisai; Johnson & Johnson; Merck; MSD Oncology; Novartis; Olympus; Ono Pharmaceutical; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Janssen Oncology; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Kissei Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Takeda (Inst)
 
Takahiro Osawa
No Relationships to Disclose
 
Takashige Abe
No Relationships to Disclose
 
Nobuo Shinohara
Honoraria - Astellas Pharma; AstraZeneca; Janssen; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst)
 
Yota Yasumizu
No Relationships to Disclose
 
Nobuyuki Tanaka
No Relationships to Disclose
 
Mototsugu Oya
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Bayer
Research Funding - Astellas Pharma
 
Koshiro Nishimoto
No Relationships to Disclose
 
Satoshi Horasawa
No Relationships to Disclose
 
Naomi Kuramoto
No Relationships to Disclose
 
Yoshiaki Nakamura
Research Funding - Genomedia (Inst); Guardant Health (Inst); Taiho Pharmaceutical (Inst)
 
Hiroya Taniguchi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.; Merck Serono; Mitsubishi Tanabe Pharma; MSD K.K; Nippon Kayaku; Novartis; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Array BioPharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; MSD Oncology; Novartis; Ono Pharmaceutical; Sysmex; Takeda
 
Takayuki Yoshino
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Norio Nonomura
Honoraria - Astellas Pharma; AstraZeneca; Asuka Seiyaku; Bayer; Bristol-Myers Squibb; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; Kyorin; MSD; Nippon Shinyaku; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Asuka Seiyaku (Inst); Chugai Pharma (Inst); Daiichi-Sankyo (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); MSD (Inst); Nippon Kayaku (Inst); Nippon Shinyaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst)